Source: Eur Respir J 2012; 40: 306-312
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Stolk Jan, Stockley Robert A., Stoel Berend C., Cooper Brendan G., Piitulainen Eeva, Seersholm Niels, Chapman Kenneth R., Burdon Jonathan G.W., Decramer Marc, Abboud Raja T., Mannes Gregorius P.M., Wouters Emiel F., Garrett Jeffrey E., Barros-Tizon Juan C., Russi Erich W., Lomas David A., MacNee William A., Rames Alexis. Randomised controlled trial for emphysema with a selective agonist of the ?-type retinoic acid receptor. Eur Respir J 2012; 40: 306-312

Member's Comments

No comment yet.

Related content which might interest you: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002 A randomised, controlled trial of bosentan in severe COPD Source: Eur Respir J 2008; 32: 619-628 Year: 2008 Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 Short term glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: "REDUCE*", a non-inferiority multicenter trial. (*Reduction in the Use of Corticosteroids in Exacerbated COPD; ISRCTN19646069) Source: Annual Congress 2012 - Acute exacerbation in COPD Year: 2012 The effects of oral clarithromycin on airway inflammation in moderate to severe chronic obstructive pulmonary disease (COPD) - a double blind randomised controlled trial Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007 Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough Source: ERJ Open Res, 6 (4) 00284-2020; 10.1183/23120541.00284-2020 Year: 2020 Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Source: Eur Respir J 2006; 27: 972-979 Year: 2006 Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 Cilomilast reduces CD8+ T-lymphocytes and macrophages in patients with chronic obstructive pulmonary disease (COPD): a double-blind placebo-controlled, parallel-group quantitative study of bronchial biopsies Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001 Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002 Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 The utility of tiotropium among patients with chronic obstructive pulmonary disease (COPD): An updated meta-analysis of randomized controlled trials Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Design of phase 2b randomised controlled trial of S-600918, P2X3 receptor antagonist for refractory chronic cough Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Effects of Roflumilast on subclinical atherosclerosis in COPD - a randomized controlled trial Source: International Congress 2017 – Extrapulmonary comorbidities in COPD Year: 2017 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008